 Joseph Saseen
Concepts (451)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 23 | 2022 | 373 | 4.600 |
Why?
| | Pharmacists | 17 | 2023 | 233 | 2.910 |
Why?
| | Hypertension | 22 | 2021 | 1056 | 2.660 |
Why?
| | Antihypertensive Agents | 13 | 2021 | 429 | 2.240 |
Why?
| | Cardiovascular Diseases | 18 | 2022 | 1727 | 2.100 |
Why?
| | Atherosclerosis | 5 | 2022 | 341 | 1.980 |
Why?
| | Students, Pharmacy | 7 | 2018 | 98 | 1.920 |
Why?
| | Cholesterol, LDL | 11 | 2021 | 307 | 1.840 |
Why?
| | Hypercholesterolemia | 7 | 2021 | 90 | 1.590 |
Why?
| | Educational Measurement | 5 | 2018 | 243 | 1.590 |
Why?
| | Hypolipidemic Agents | 8 | 2021 | 86 | 1.530 |
Why?
| | Professional Role | 7 | 2020 | 149 | 1.470 |
Why?
| | Education, Pharmacy | 7 | 2018 | 123 | 1.450 |
Why?
| | Practice Guidelines as Topic | 13 | 2020 | 1394 | 1.330 |
Why?
| | Medication Therapy Management | 5 | 2018 | 67 | 1.280 |
Why?
| | Anticholesteremic Agents | 7 | 2021 | 128 | 1.260 |
Why?
| | Dyslipidemias | 7 | 2016 | 154 | 1.240 |
Why?
| | Lipids | 3 | 2022 | 580 | 1.220 |
Why?
| | Ambulatory Care | 9 | 2018 | 478 | 1.180 |
Why?
| | Cholesterol | 5 | 2020 | 367 | 1.160 |
Why?
| | Calcium Channel Blockers | 7 | 2015 | 114 | 1.140 |
Why?
| | Managed Care Programs | 4 | 2014 | 133 | 1.080 |
Why?
| | Practice Patterns, Physicians' | 5 | 2023 | 1177 | 1.000 |
Why?
| | Societies, Pharmaceutical | 7 | 2017 | 27 | 1.000 |
Why?
| | Humans | 127 | 2023 | 114674 | 0.990 |
Why?
| | Blood Pressure | 11 | 2021 | 1538 | 0.970 |
Why?
| | Chlorthalidone | 2 | 2014 | 5 | 0.960 |
Why?
| | Hydrochlorothiazide | 2 | 2014 | 8 | 0.960 |
Why?
| | Pharmaceutical Services | 5 | 2020 | 77 | 0.940 |
Why?
| | Arthritis, Gouty | 2 | 2016 | 14 | 0.940 |
Why?
| | Urinary Tract Infections | 2 | 2023 | 134 | 0.900 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2018 | 299 | 0.890 |
Why?
| | Adrenergic beta-Antagonists | 4 | 2014 | 287 | 0.870 |
Why?
| | Retrospective Studies | 34 | 2023 | 12549 | 0.870 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 900 | 0.850 |
Why?
| | Education, Pharmacy, Graduate | 4 | 2017 | 21 | 0.850 |
Why?
| | Pharmacy Residencies | 3 | 2018 | 12 | 0.850 |
Why?
| | Clinical Competence | 4 | 2018 | 893 | 0.850 |
Why?
| | American Heart Association | 4 | 2020 | 264 | 0.840 |
Why?
| | Blood Glucose | 4 | 2017 | 1828 | 0.830 |
Why?
| | Coronary Artery Disease | 3 | 2021 | 607 | 0.770 |
Why?
| | Hypoglycemic Agents | 4 | 2014 | 1013 | 0.770 |
Why?
| | Gout | 3 | 2020 | 36 | 0.770 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2022 | 2096 | 0.760 |
Why?
| | Diuretics | 4 | 2014 | 66 | 0.750 |
Why?
| | Dicarboxylic Acids | 1 | 2021 | 6 | 0.750 |
Why?
| | Evidence-Based Medicine | 14 | 2018 | 668 | 0.740 |
Why?
| | Preceptorship | 2 | 2018 | 62 | 0.740 |
Why?
| | Serotonin 5-HT1 Receptor Agonists | 1 | 2020 | 3 | 0.740 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2011 | 179 | 0.740 |
Why?
| | Drug Prescriptions | 2 | 2020 | 239 | 0.730 |
Why?
| | Teaching | 3 | 2018 | 213 | 0.720 |
Why?
| | Aged | 33 | 2023 | 19073 | 0.720 |
Why?
| | Middle Aged | 37 | 2023 | 26735 | 0.690 |
Why?
| | Primary Health Care | 8 | 2023 | 1513 | 0.680 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 1815 | 0.680 |
Why?
| | Muscular Diseases | 2 | 2015 | 104 | 0.670 |
Why?
| | Migraine Disorders | 1 | 2020 | 82 | 0.660 |
Why?
| | Health Benefit Plans, Employee | 2 | 2017 | 20 | 0.640 |
Why?
| | Drug Therapy | 2 | 2017 | 76 | 0.620 |
Why?
| | Fatty Acids | 1 | 2021 | 381 | 0.600 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 96 | 0.600 |
Why?
| | Acetaminophen | 3 | 2007 | 241 | 0.600 |
Why?
| | Insurance Coverage | 2 | 2011 | 200 | 0.590 |
Why?
| | Simvastatin | 3 | 2015 | 59 | 0.570 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 48 | 0.550 |
Why?
| | Faculty, Pharmacy | 1 | 2017 | 17 | 0.550 |
Why?
| | Research | 2 | 2017 | 394 | 0.550 |
Why?
| | Adult | 31 | 2021 | 30546 | 0.540 |
Why?
| | Female | 47 | 2020 | 59499 | 0.530 |
Why?
| | Population Health | 1 | 2017 | 42 | 0.530 |
Why?
| | HIV | 1 | 2017 | 208 | 0.530 |
Why?
| | Cardiology | 4 | 2018 | 259 | 0.520 |
Why?
| | Heart Failure | 3 | 2023 | 1945 | 0.520 |
Why?
| | Male | 42 | 2020 | 55589 | 0.520 |
Why?
| | Perception | 1 | 2018 | 311 | 0.510 |
Why?
| | Aged, 80 and over | 13 | 2020 | 6347 | 0.510 |
Why?
| | Anti-Retroviral Agents | 1 | 2017 | 207 | 0.500 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 184 | 0.500 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 249 | 0.500 |
Why?
| | Hyperlipidemias | 5 | 2018 | 121 | 0.500 |
Why?
| | Faculty, Medical | 1 | 2017 | 228 | 0.490 |
Why?
| | Poverty | 2 | 2008 | 442 | 0.470 |
Why?
| | Primary Prevention | 2 | 2021 | 172 | 0.470 |
Why?
| | United States | 22 | 2022 | 12182 | 0.460 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 2 | 2013 | 29 | 0.460 |
Why?
| | Program Evaluation | 3 | 2017 | 822 | 0.460 |
Why?
| | Gout Suppressants | 2 | 2020 | 20 | 0.450 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2007 | 120 | 0.450 |
Why?
| | Self Report | 1 | 2017 | 696 | 0.440 |
Why?
| | Drug Therapy, Combination | 12 | 2020 | 951 | 0.440 |
Why?
| | Curriculum | 6 | 2018 | 819 | 0.440 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 771 | 0.440 |
Why?
| | Tetrazoles | 1 | 2013 | 32 | 0.440 |
Why?
| | Ezetimibe | 4 | 2021 | 24 | 0.430 |
Why?
| | Adrenal Cortex Hormones | 2 | 2016 | 497 | 0.420 |
Why?
| | Gemfibrozil | 3 | 2016 | 9 | 0.420 |
Why?
| | Osteoarthritis | 2 | 2006 | 171 | 0.420 |
Why?
| | Anti-Arrhythmia Agents | 2 | 2003 | 106 | 0.410 |
Why?
| | Treatment Outcome | 16 | 2021 | 9088 | 0.410 |
Why?
| | Imidazoles | 1 | 2013 | 208 | 0.410 |
Why?
| | Electronic Health Records | 5 | 2018 | 800 | 0.400 |
Why?
| | Venoms | 1 | 2012 | 30 | 0.400 |
Why?
| | Kidney | 1 | 2019 | 1188 | 0.400 |
Why?
| | Health Expenditures | 5 | 2017 | 171 | 0.390 |
Why?
| | Colorado | 12 | 2023 | 4099 | 0.390 |
Why?
| | Lipoprotein(a) | 2 | 2022 | 51 | 0.390 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 486 | 0.380 |
Why?
| | Problem-Based Learning | 3 | 2017 | 78 | 0.380 |
Why?
| | Health Resources | 1 | 2012 | 122 | 0.370 |
Why?
| | Risk Assessment | 11 | 2022 | 2968 | 0.360 |
Why?
| | Risk Factors | 16 | 2022 | 8632 | 0.360 |
Why?
| | Medicare Part D | 1 | 2011 | 26 | 0.360 |
Why?
| | Arthritis, Rheumatoid | 3 | 2009 | 1003 | 0.350 |
Why?
| | Insurance Claim Review | 3 | 2017 | 67 | 0.340 |
Why?
| | Azetidines | 2 | 2008 | 31 | 0.330 |
Why?
| | Antibodies, Monoclonal | 4 | 2020 | 1262 | 0.320 |
Why?
| | Drug Interactions | 4 | 2022 | 338 | 0.320 |
Why?
| | Clinical Trials as Topic | 8 | 2017 | 932 | 0.310 |
Why?
| | Antirheumatic Agents | 2 | 2009 | 255 | 0.310 |
Why?
| | Age Factors | 5 | 2017 | 2894 | 0.310 |
Why?
| | Cohort Studies | 10 | 2020 | 4895 | 0.310 |
Why?
| | Venous Thromboembolism | 2 | 2022 | 231 | 0.300 |
Why?
| | Community Health Centers | 2 | 2018 | 54 | 0.300 |
Why?
| | HIV Infections | 2 | 2023 | 2469 | 0.300 |
Why?
| | Drug Costs | 2 | 2006 | 92 | 0.290 |
Why?
| | Weight Loss | 3 | 2012 | 642 | 0.290 |
Why?
| | Young Adult | 9 | 2021 | 10466 | 0.290 |
Why?
| | Kidney Failure, Chronic | 2 | 2010 | 489 | 0.290 |
Why?
| | Peptides | 1 | 2012 | 848 | 0.280 |
Why?
| | Family Practice | 4 | 2015 | 427 | 0.280 |
Why?
| | Verapamil | 2 | 1997 | 32 | 0.280 |
Why?
| | Certification | 2 | 2006 | 89 | 0.280 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2007 | 44 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2007 | 1214 | 0.270 |
Why?
| | Renal Dialysis | 1 | 2010 | 374 | 0.270 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2007 | 81 | 0.270 |
Why?
| | Aspirin | 2 | 2008 | 324 | 0.270 |
Why?
| | Tablets | 1 | 2006 | 36 | 0.270 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2006 | 20 | 0.260 |
Why?
| | Drug Compounding | 1 | 2006 | 89 | 0.260 |
Why?
| | Lipoproteins | 1 | 2007 | 159 | 0.260 |
Why?
| | Patient Care | 3 | 2017 | 101 | 0.260 |
Why?
| | Insurance, Health | 4 | 2015 | 244 | 0.260 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2007 | 125 | 0.250 |
Why?
| | Sodium Chloride, Dietary | 1 | 2006 | 30 | 0.250 |
Why?
| | Guideline Adherence | 3 | 2020 | 490 | 0.250 |
Why?
| | Ambulatory Care Facilities | 2 | 2017 | 213 | 0.250 |
Why?
| | Benzothiadiazines | 1 | 2005 | 3 | 0.250 |
Why?
| | Blood Pressure Determination | 3 | 2018 | 122 | 0.250 |
Why?
| | Sodium Chloride Symporter Inhibitors | 1 | 2005 | 9 | 0.250 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 102 | 0.240 |
Why?
| | Societies, Medical | 3 | 2019 | 663 | 0.240 |
Why?
| | Brain Ischemia | 1 | 2008 | 299 | 0.240 |
Why?
| | Glomerular Filtration Rate | 2 | 2019 | 604 | 0.240 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2008 | 401 | 0.240 |
Why?
| | Drug Labeling | 3 | 2015 | 42 | 0.240 |
Why?
| | Quality Assurance, Health Care | 1 | 2006 | 311 | 0.230 |
Why?
| | Bronchiolitis, Viral | 1 | 2004 | 10 | 0.230 |
Why?
| | Patient-Centered Care | 3 | 2015 | 473 | 0.230 |
Why?
| | Incidence | 3 | 2023 | 2313 | 0.220 |
Why?
| | Life Style | 1 | 2006 | 430 | 0.220 |
Why?
| | Hormone Replacement Therapy | 1 | 2004 | 77 | 0.220 |
Why?
| | Off-Label Use | 2 | 2015 | 51 | 0.220 |
Why?
| | Contraceptive Agents | 1 | 2004 | 54 | 0.210 |
Why?
| | Progesterone Congeners | 1 | 2003 | 14 | 0.210 |
Why?
| | Medroxyprogesterone | 1 | 2003 | 10 | 0.210 |
Why?
| | Quality Indicators, Health Care | 1 | 2005 | 287 | 0.210 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2003 | 34 | 0.210 |
Why?
| | Epinephrine | 1 | 2004 | 163 | 0.210 |
Why?
| | Faculty | 2 | 2018 | 130 | 0.210 |
Why?
| | C-Reactive Protein | 1 | 2005 | 362 | 0.210 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2007 | 1140 | 0.200 |
Why?
| | Heart Conduction System | 1 | 2003 | 80 | 0.200 |
Why?
| | Contraception | 1 | 2004 | 117 | 0.200 |
Why?
| | Death, Sudden, Cardiac | 1 | 2003 | 160 | 0.200 |
Why?
| | Program Development | 2 | 2017 | 341 | 0.200 |
Why?
| | Bronchodilator Agents | 1 | 2004 | 239 | 0.200 |
Why?
| | Estrogen Replacement Therapy | 1 | 2003 | 116 | 0.200 |
Why?
| | Attitude to Health | 1 | 2005 | 406 | 0.190 |
Why?
| | Communicable Diseases | 1 | 2023 | 129 | 0.190 |
Why?
| | Antiphospholipid Syndrome | 1 | 2021 | 26 | 0.190 |
Why?
| | Atenolol | 2 | 2014 | 6 | 0.190 |
Why?
| | Text Messaging | 1 | 2023 | 152 | 0.180 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 179 | 0.180 |
Why?
| | Vasodilator Agents | 1 | 2003 | 302 | 0.180 |
Why?
| | Patient Care Team | 4 | 2022 | 517 | 0.180 |
Why?
| | Adolescent | 7 | 2020 | 17841 | 0.180 |
Why?
| | Drug Tolerance | 1 | 2021 | 79 | 0.180 |
Why?
| | Transition to Adult Care | 1 | 2022 | 62 | 0.180 |
Why?
| | Diabetic Nephropathies | 1 | 2004 | 234 | 0.180 |
Why?
| | Xanthine Oxidase | 2 | 2020 | 71 | 0.180 |
Why?
| | Costs and Cost Analysis | 3 | 2014 | 196 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2014 | 1842 | 0.170 |
Why?
| | Public Health Administration | 1 | 2021 | 75 | 0.170 |
Why?
| | Stroke | 1 | 2008 | 1022 | 0.170 |
Why?
| | Dipyrone | 1 | 1999 | 1 | 0.170 |
Why?
| | Pharmacy Service, Hospital | 2 | 2013 | 83 | 0.170 |
Why?
| | Methenamine | 1 | 2019 | 4 | 0.170 |
Why?
| | Appetite Stimulants | 1 | 1999 | 2 | 0.170 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2019 | 13 | 0.170 |
Why?
| | HIV Wasting Syndrome | 1 | 1999 | 4 | 0.170 |
Why?
| | Diltiazem | 2 | 1996 | 23 | 0.170 |
Why?
| | Anabolic Agents | 1 | 1999 | 11 | 0.170 |
Why?
| | Nifedipine | 2 | 1996 | 29 | 0.170 |
Why?
| | Drug and Narcotic Control | 1 | 1999 | 29 | 0.170 |
Why?
| | Heart Rate | 1 | 2003 | 709 | 0.160 |
Why?
| | Atrial Fibrillation | 1 | 2003 | 322 | 0.160 |
Why?
| | Proprotein Convertase 9 | 1 | 2019 | 61 | 0.160 |
Why?
| | Protons | 1 | 2019 | 73 | 0.160 |
Why?
| | Internship, Nonmedical | 3 | 2011 | 18 | 0.160 |
Why?
| | Secondary Prevention | 2 | 2021 | 222 | 0.160 |
Why?
| | Guidelines as Topic | 2 | 2019 | 243 | 0.150 |
Why?
| | Training Support | 1 | 2018 | 22 | 0.150 |
Why?
| | Thrombosis | 1 | 2021 | 298 | 0.150 |
Why?
| | Federal Government | 1 | 2018 | 26 | 0.150 |
Why?
| | Health Services | 2 | 2009 | 103 | 0.150 |
Why?
| | Risk | 2 | 2017 | 812 | 0.150 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1999 | 217 | 0.150 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2539 | 0.150 |
Why?
| | Medically Underserved Area | 1 | 2018 | 80 | 0.150 |
Why?
| | Anticoagulants | 4 | 2022 | 550 | 0.140 |
Why?
| | Quality of Health Care | 2 | 2017 | 573 | 0.140 |
Why?
| | Vulnerable Populations | 1 | 2018 | 133 | 0.140 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 666 | 0.140 |
Why?
| | Models, Econometric | 1 | 2017 | 34 | 0.140 |
Why?
| | Point-of-Care Systems | 1 | 2018 | 136 | 0.140 |
Why?
| | Warfarin | 3 | 2021 | 135 | 0.140 |
Why?
| | United States Food and Drug Administration | 2 | 2015 | 172 | 0.140 |
Why?
| | Colchicine | 1 | 2016 | 24 | 0.140 |
Why?
| | Alcoholism | 1 | 2003 | 713 | 0.130 |
Why?
| | Protease Inhibitors | 1 | 2017 | 97 | 0.130 |
Why?
| | Chronic Disease | 3 | 2013 | 1578 | 0.130 |
Why?
| | Comorbidity | 4 | 2016 | 1448 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 43 | 0.130 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4622 | 0.130 |
Why?
| | Exercise | 1 | 2006 | 1644 | 0.130 |
Why?
| | Education, Medical, Undergraduate | 1 | 2017 | 159 | 0.120 |
Why?
| | Uric Acid | 1 | 2016 | 148 | 0.120 |
Why?
| | Amlodipine | 1 | 2015 | 8 | 0.120 |
Why?
| | Liver | 1 | 2003 | 1637 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 14 | 0.120 |
Why?
| | Patient Education as Topic | 2 | 2012 | 680 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2016 | 4411 | 0.120 |
Why?
| | Systole | 1 | 2014 | 171 | 0.120 |
Why?
| | Benzopyrans | 1 | 2014 | 25 | 0.110 |
Why?
| | Ethanolamines | 1 | 2014 | 19 | 0.110 |
Why?
| | Nebivolol | 1 | 2014 | 9 | 0.110 |
Why?
| | Metoprolol | 1 | 2014 | 37 | 0.110 |
Why?
| | Risk Reduction Behavior | 3 | 2022 | 201 | 0.110 |
Why?
| | Losartan | 1 | 2013 | 9 | 0.110 |
Why?
| | Carbazoles | 1 | 2014 | 78 | 0.110 |
Why?
| | Valsartan | 1 | 2013 | 22 | 0.110 |
Why?
| | Propanolamines | 1 | 2014 | 90 | 0.110 |
Why?
| | Medicaid | 1 | 2017 | 407 | 0.110 |
Why?
| | Drug Substitution | 1 | 2013 | 46 | 0.110 |
Why?
| | Biphenyl Compounds | 1 | 2013 | 50 | 0.110 |
Why?
| | Biomarkers | 5 | 2018 | 3408 | 0.110 |
Why?
| | Valine | 1 | 2013 | 72 | 0.110 |
Why?
| | Patient Acceptance of Health Care | 2 | 2012 | 681 | 0.110 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1078 | 0.100 |
Why?
| | Telemedicine | 1 | 2021 | 662 | 0.100 |
Why?
| | Antidepressive Agents, Second-Generation | 2 | 2004 | 38 | 0.100 |
Why?
| | Internship and Residency | 2 | 2017 | 926 | 0.100 |
Why?
| | Fibric Acids | 1 | 2012 | 2 | 0.100 |
Why?
| | Decision Support Systems, Clinical | 1 | 2015 | 176 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2005 | 2763 | 0.100 |
Why?
| | Contraindications | 1 | 2012 | 85 | 0.100 |
Why?
| | Drug Combinations | 2 | 2016 | 287 | 0.100 |
Why?
| | Double-Blind Method | 4 | 2003 | 1660 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2018 | 638 | 0.100 |
Why?
| | Sex Factors | 1 | 2017 | 1715 | 0.100 |
Why?
| | Age Distribution | 1 | 2012 | 342 | 0.100 |
Why?
| | Consensus | 3 | 2018 | 537 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 498 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2014 | 341 | 0.090 |
Why?
| | Annual Reports as Topic | 1 | 2010 | 5 | 0.090 |
Why?
| | Professional Staff Committees | 1 | 2010 | 14 | 0.090 |
Why?
| | Financing, Personal | 1 | 2011 | 25 | 0.090 |
Why?
| | Insurance Benefits | 1 | 2010 | 11 | 0.090 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2010 | 23 | 0.090 |
Why?
| | Creatinine | 1 | 2012 | 425 | 0.090 |
Why?
| | Pharmacy | 1 | 2010 | 28 | 0.090 |
Why?
| | Nutrition Surveys | 2 | 2021 | 224 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2012 | 1226 | 0.080 |
Why?
| | Hypoglycemia | 1 | 2014 | 387 | 0.080 |
Why?
| | Drug Utilization Review | 2 | 2006 | 57 | 0.080 |
Why?
| | Hyperlipoproteinemia Type II | 2 | 2019 | 26 | 0.080 |
Why?
| | Prescription Drugs | 1 | 2010 | 116 | 0.080 |
Why?
| | Dipyridamole | 1 | 2008 | 25 | 0.080 |
Why?
| | Ezetimibe, Simvastatin Drug Combination | 1 | 2008 | 1 | 0.080 |
Why?
| | Fluorobenzenes | 1 | 2008 | 11 | 0.080 |
Why?
| | Rosuvastatin Calcium | 1 | 2008 | 17 | 0.080 |
Why?
| | Patient Compliance | 3 | 2008 | 525 | 0.080 |
Why?
| | Ticlopidine | 1 | 2008 | 55 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2007 | 718 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1183 | 0.070 |
Why?
| | Abatacept | 1 | 2007 | 40 | 0.070 |
Why?
| | Ischemic Attack, Transient | 1 | 2008 | 62 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1075 | 0.070 |
Why?
| | Hemorrhage | 2 | 2022 | 620 | 0.070 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 82 | 0.070 |
Why?
| | Dipeptidyl Peptidase 4 | 1 | 2007 | 11 | 0.070 |
Why?
| | Adamantane | 1 | 2007 | 16 | 0.070 |
Why?
| | Timolol | 1 | 2007 | 14 | 0.070 |
Why?
| | Propranolol | 1 | 2007 | 49 | 0.070 |
Why?
| | Contraception, Postcoital | 1 | 2007 | 6 | 0.070 |
Why?
| | Accreditation | 1 | 2007 | 76 | 0.070 |
Why?
| | Pyrrolidines | 1 | 2007 | 55 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 42 | 0.070 |
Why?
| | Rituximab | 1 | 2007 | 150 | 0.070 |
Why?
| | Levonorgestrel | 1 | 2007 | 31 | 0.070 |
Why?
| | Specialty Boards | 1 | 2006 | 32 | 0.070 |
Why?
| | Immunoconjugates | 1 | 2007 | 87 | 0.070 |
Why?
| | Nitriles | 1 | 2007 | 149 | 0.070 |
Why?
| | Anti-Ulcer Agents | 1 | 2006 | 16 | 0.070 |
Why?
| | Cost Savings | 1 | 2006 | 74 | 0.070 |
Why?
| | Delivery of Health Care | 3 | 2022 | 833 | 0.070 |
Why?
| | Medication Errors | 1 | 2006 | 88 | 0.060 |
Why?
| | Safety Management | 1 | 2006 | 109 | 0.060 |
Why?
| | Pyrimidines | 1 | 2008 | 376 | 0.060 |
Why?
| | Child, Preschool | 2 | 2017 | 9114 | 0.060 |
Why?
| | Case Management | 1 | 2005 | 62 | 0.060 |
Why?
| | Efficiency, Organizational | 1 | 2005 | 125 | 0.060 |
Why?
| | Sulfonamides | 1 | 2008 | 445 | 0.060 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 165 | 0.060 |
Why?
| | Benchmarking | 1 | 2005 | 161 | 0.060 |
Why?
| | Nephrology | 1 | 2005 | 48 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2387 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 750 | 0.060 |
Why?
| | Professional-Patient Relations | 1 | 2005 | 141 | 0.060 |
Why?
| | Coronary Disease | 2 | 2003 | 348 | 0.060 |
Why?
| | Rhabdomyolysis | 1 | 2003 | 16 | 0.060 |
Why?
| | Medicare | 1 | 2009 | 665 | 0.060 |
Why?
| | Amiodarone | 1 | 2003 | 23 | 0.050 |
Why?
| | Albuterol | 1 | 2004 | 102 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 1879 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2004 | 158 | 0.050 |
Why?
| | Disease Susceptibility | 1 | 2005 | 316 | 0.050 |
Why?
| | Liver Function Tests | 1 | 2003 | 103 | 0.050 |
Why?
| | Endpoint Determination | 1 | 2003 | 68 | 0.050 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 11 | 0.050 |
Why?
| | Nocebo Effect | 1 | 2022 | 9 | 0.050 |
Why?
| | Cyclohexanols | 1 | 2002 | 9 | 0.050 |
Why?
| | Physician-Patient Relations | 1 | 2006 | 462 | 0.050 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 228 | 0.050 |
Why?
| | Vaginal Diseases | 1 | 2002 | 17 | 0.050 |
Why?
| | Information Dissemination | 1 | 2004 | 186 | 0.050 |
Why?
| | Women's Health | 1 | 2004 | 271 | 0.050 |
Why?
| | Reminder Systems | 1 | 2023 | 160 | 0.050 |
Why?
| | Kidney Diseases | 1 | 2005 | 350 | 0.050 |
Why?
| | Sodium | 1 | 2022 | 183 | 0.050 |
Why?
| | Acute Disease | 1 | 2004 | 911 | 0.050 |
Why?
| | Vitamin K 1 | 1 | 2000 | 2 | 0.050 |
Why?
| | Postmenopause | 1 | 2003 | 303 | 0.050 |
Why?
| | Symptom Flare Up | 1 | 2020 | 38 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2097 | 0.040 |
Why?
| | Liver Diseases | 1 | 2003 | 255 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 186 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2004 | 578 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 1796 | 0.040 |
Why?
| | Health Plan Implementation | 1 | 2021 | 132 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2021 | 211 | 0.040 |
Why?
| | Medical Audit | 2 | 2013 | 75 | 0.040 |
Why?
| | Antifibrinolytic Agents | 1 | 2000 | 50 | 0.040 |
Why?
| | Europe | 1 | 2020 | 334 | 0.040 |
Why?
| | Child | 2 | 2017 | 18412 | 0.040 |
Why?
| | Administration, Oral | 1 | 2021 | 728 | 0.040 |
Why?
| | Software | 1 | 2023 | 530 | 0.040 |
Why?
| | Ibuprofen | 1 | 1999 | 75 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2019 | 140 | 0.040 |
Why?
| | Drug Hypersensitivity | 1 | 2000 | 83 | 0.040 |
Why?
| | Societies, Scientific | 1 | 2019 | 47 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2000 | 218 | 0.040 |
Why?
| | Student Health Services | 1 | 2018 | 16 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2022 | 561 | 0.040 |
Why?
| | Self Care | 1 | 2000 | 349 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4408 | 0.040 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 1999 | 256 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 897 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 581 | 0.040 |
Why?
| | Public Health | 1 | 2021 | 433 | 0.030 |
Why?
| | Homozygote | 1 | 2017 | 187 | 0.030 |
Why?
| | Felodipine | 1 | 1996 | 4 | 0.030 |
Why?
| | Receptors, Drug | 1 | 1996 | 12 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 544 | 0.030 |
Why?
| | Polypharmacy | 1 | 2016 | 74 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 772 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 1997 | 440 | 0.030 |
Why?
| | Calcium Channels | 1 | 1996 | 145 | 0.030 |
Why?
| | Communication | 2 | 2014 | 744 | 0.030 |
Why?
| | Internet | 1 | 1999 | 596 | 0.030 |
Why?
| | Medication Adherence | 2 | 2010 | 536 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 663 | 0.030 |
Why?
| | Myocardial Ischemia | 1 | 1996 | 235 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 1996 | 321 | 0.030 |
Why?
| | Regression Analysis | 2 | 2009 | 944 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 268 | 0.030 |
Why?
| | Pain | 1 | 1999 | 705 | 0.030 |
Why?
| | Infant | 2 | 2004 | 7961 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1317 | 0.030 |
Why?
| | Hemodynamics | 1 | 1997 | 1012 | 0.030 |
Why?
| | Comprehension | 1 | 2014 | 156 | 0.030 |
Why?
| | Educational Status | 1 | 2014 | 412 | 0.020 |
Why?
| | Adrenergic Antagonists | 1 | 2011 | 9 | 0.020 |
Why?
| | Renin | 1 | 2011 | 31 | 0.020 |
Why?
| | Prospective Studies | 3 | 2015 | 6219 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2003 | 1862 | 0.020 |
Why?
| | Phytotherapy | 1 | 2011 | 66 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2000 | 1481 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.020 |
Why?
| | Drug Utilization | 1 | 2011 | 167 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2010 | 71 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1373 | 0.020 |
Why?
| | Likelihood Functions | 1 | 2010 | 126 | 0.020 |
Why?
| | Models, Organizational | 1 | 2011 | 140 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3003 | 0.020 |
Why?
| | Preferred Provider Organizations | 1 | 2009 | 4 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 2796 | 0.020 |
Why?
| | Transportation | 1 | 2009 | 44 | 0.020 |
Why?
| | Private Sector | 1 | 2009 | 51 | 0.020 |
Why?
| | Interprofessional Relations | 1 | 2011 | 249 | 0.020 |
Why?
| | Infliximab | 1 | 2009 | 94 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2011 | 381 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 2353 | 0.020 |
Why?
| | North America | 1 | 2009 | 256 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1430 | 0.020 |
Why?
| | Organizational Policy | 1 | 2006 | 68 | 0.020 |
Why?
| | Time Factors | 1 | 1996 | 6115 | 0.020 |
Why?
| | Professional Practice | 1 | 2006 | 62 | 0.020 |
Why?
| | Health Care Costs | 1 | 2009 | 381 | 0.020 |
Why?
| | Logistic Models | 1 | 2010 | 1841 | 0.020 |
Why?
| | Role | 1 | 2005 | 32 | 0.020 |
Why?
| | Bone Diseases, Metabolic | 1 | 2005 | 53 | 0.010 |
Why?
| | Expert Testimony | 1 | 2005 | 36 | 0.010 |
Why?
| | Interdisciplinary Communication | 1 | 2005 | 183 | 0.010 |
Why?
| | Models, Economic | 1 | 2004 | 48 | 0.010 |
Why?
| | Review Literature as Topic | 1 | 2004 | 61 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2005 | 211 | 0.010 |
Why?
| | Probability | 1 | 2004 | 289 | 0.010 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2002 | 11 | 0.010 |
Why?
| | Menstruation | 1 | 2002 | 35 | 0.010 |
Why?
| | International Normalized Ratio | 1 | 2000 | 45 | 0.010 |
Why?
| | Health Maintenance Organizations | 1 | 2000 | 93 | 0.010 |
Why?
| | Hospitalization | 1 | 2009 | 1752 | 0.010 |
Why?
| | beta-Lactams | 1 | 2000 | 27 | 0.010 |
Why?
| | Medical Records | 1 | 2000 | 153 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1692 | 0.010 |
Why?
| | Prevalence | 1 | 2005 | 2251 | 0.010 |
Why?
| | Depressive Disorder | 1 | 2002 | 332 | 0.010 |
Why?
| | Depression | 1 | 2004 | 1134 | 0.010 |
Why?
|
|
Saseen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|